Dr. Delphine Rea - Chronic Myeloid Leukemia - CML
Dr Delphine Rea,
Unité de Thérapie Cellulaire et Clinique Transfusionnelle,
Hôpital Saint Louis, 1, avenue Claude Vellefaux,
75010 Paris, France
Unité de Thérapie Cellulaire et Clinique Transfusionnelle,
Hôpital Saint Louis, 1, avenue Claude Vellefaux,
75010 Paris, France
VIDEOS in English
TFR - a new treatment goal of CP-CML patients?
August 2018, iCMLf
VEP 2017: Factors affecting clinical decision making
2017, iCMLf
Comorbidities when managing CML
December 2, 2016, iCMLf forum
Can we safely stop TKI therapies? Experience from the STOP trials
December 2012, iCMLf
New drugs on the CML horizon; choosing the correct therapies
Prof Giuseppe Saglio - University of Turin, Italy;
Dr Delphine Rea - Saint Louis Hospital, Paris;
Jan Geissler - Co-Founder, CML Advocates Network
December 8, 2011, ecancer.tv
VIDEOS in French
Traitement par imatinib de la leucémie myéloïde chronique 20 ans après par Delphine REA
21 mars 2023, Académie nationale de médecine
5 questions sur la LMC
April 14,2022, Hôpital St-Louis
L'étude IMMUNOSTIM
January 16 2016, LMC FRANCE
Docteur Delphine Réa, hématologue : essais cliniques et LMC
December 29, 2014, LMC France
Peut-on arrêter en toute sécurité un traitement par ITK ? Les enseignements des essais STOP
Décembre 2012, iCMLf
TFR - a new treatment goal of CP-CML patients?
August 2018, iCMLf
VEP 2017: Factors affecting clinical decision making
2017, iCMLf
Comorbidities when managing CML
December 2, 2016, iCMLf forum
Can we safely stop TKI therapies? Experience from the STOP trials
December 2012, iCMLf
New drugs on the CML horizon; choosing the correct therapies
Prof Giuseppe Saglio - University of Turin, Italy;
Dr Delphine Rea - Saint Louis Hospital, Paris;
Jan Geissler - Co-Founder, CML Advocates Network
December 8, 2011, ecancer.tv
VIDEOS in French
Traitement par imatinib de la leucémie myéloïde chronique 20 ans après par Delphine REA
21 mars 2023, Académie nationale de médecine
5 questions sur la LMC
April 14,2022, Hôpital St-Louis
L'étude IMMUNOSTIM
January 16 2016, LMC FRANCE
Docteur Delphine Réa, hématologue : essais cliniques et LMC
December 29, 2014, LMC France
Peut-on arrêter en toute sécurité un traitement par ITK ? Les enseignements des essais STOP
Décembre 2012, iCMLf
ARTICLES
COVID-19 in Patients (pts) with Chronic Myeloid Leukemia (CML): Results from the International CML Foundation (iCMLf) CML and COVID-19 (CANDID) Study
December 7, 2020, ASH 2020
Handling challenging questions in the management of chronic myeloid leukemia: when is it safe to stop tyrosine kinase inhibitors?
November 10, 2020, Blood Advances
Asciminib, a Specific Allosteric BCR-ABL1 Inhibitor, in Patients with Chronic Myeloid Leukemia Carrying the T315I Mutation in a Phase 1 Trial
December 3, 2018, ASH2018
Case Studies in Treatment-Free Remission (TFR): The Decision-Making Process
September 1, 2018, Clinical Lymphoma , Myeloma & Leukemia
Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: Recommendations for clinical practice from the French Chronic Myeloid Leukemia Study Group
May 3, 2018, PubMed
[Management of the cardiovascular disease risk during nilotinib treatment in chronic myeloid leukemia: 2015 recommendations from the France Intergroupe des Leucémies Myéloïdes Chroniques].
February 2016, PublMed
Preliminary Report Of The STIM2 Study: A Multicenter Stop Imatinib Trial For Chronic Phase Chronic Myeloid Leukemia De Novo Patients On Imatinib
November 15, 2013, Journal Blood
First-line imatinib mesylate in patients with newly diagnosed accelerated phase-chronic myeloid leukemia
April 24, 2012, Leukemia
Imatinib plus Peginterferon Alfa-2a in Chronic Myeloid Leukemia
December 23, 2010, The New England Journal of Médicine
Lung Abnormalities after Dasatinib Treatment for Chronic Myeloid Leukemia
October 15, 2007, American Journal of Respiratory and Critical Care Medicine
COVID-19 in Patients (pts) with Chronic Myeloid Leukemia (CML): Results from the International CML Foundation (iCMLf) CML and COVID-19 (CANDID) Study
December 7, 2020, ASH 2020
Handling challenging questions in the management of chronic myeloid leukemia: when is it safe to stop tyrosine kinase inhibitors?
November 10, 2020, Blood Advances
Asciminib, a Specific Allosteric BCR-ABL1 Inhibitor, in Patients with Chronic Myeloid Leukemia Carrying the T315I Mutation in a Phase 1 Trial
December 3, 2018, ASH2018
Case Studies in Treatment-Free Remission (TFR): The Decision-Making Process
September 1, 2018, Clinical Lymphoma , Myeloma & Leukemia
Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: Recommendations for clinical practice from the French Chronic Myeloid Leukemia Study Group
May 3, 2018, PubMed
[Management of the cardiovascular disease risk during nilotinib treatment in chronic myeloid leukemia: 2015 recommendations from the France Intergroupe des Leucémies Myéloïdes Chroniques].
February 2016, PublMed
Preliminary Report Of The STIM2 Study: A Multicenter Stop Imatinib Trial For Chronic Phase Chronic Myeloid Leukemia De Novo Patients On Imatinib
November 15, 2013, Journal Blood
First-line imatinib mesylate in patients with newly diagnosed accelerated phase-chronic myeloid leukemia
April 24, 2012, Leukemia
Imatinib plus Peginterferon Alfa-2a in Chronic Myeloid Leukemia
December 23, 2010, The New England Journal of Médicine
Lung Abnormalities after Dasatinib Treatment for Chronic Myeloid Leukemia
October 15, 2007, American Journal of Respiratory and Critical Care Medicine